Targeting Na + /K + ‐ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma
出版年份 2021 全文链接
标题
Targeting Na
+
/K
+
‐ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma
作者
关键词
-
出版物
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-07-08
DOI
10.1111/bph.15616
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Redox-Sensitive Na/K-ATPase Signaling in Uremic Cardiomyopathy
- (2020) Jiang Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The p38 Pathway: From Biology to Cancer Therapy
- (2020) Adrián Martínez-Limón et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currents
- (2020) Huiyuan Hu et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Inhibitors of Na+/K+ ATPase exhibit antitumor effects on multicellular tumor spheroids of hepatocellular carcinoma
- (2020) Yeonhwa Song et al. Scientific Reports
- New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
- (2020) Zhang Cheng et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020
- (2020) Elliott Lilley et al. BRITISH JOURNAL OF PHARMACOLOGY
- Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy
- (2020) Hui Hua et al. Journal of Hematology & Oncology
- The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. JOURNAL OF PHYSIOLOGY-LONDON
- Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions
- (2020) Dhanasekhar Reddy et al. MOLECULES
- Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
- (2020) Loraine Kay D. Cabral et al. Cancers
- Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
- (2020) Jose J.G. Marin et al. Cancers
- Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis
- (2020) Giuseppe Cabibbo et al. Cancers
- The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
- (2020) Jimin Yuan et al. Journal of Hematology & Oncology
- Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
- (2020) Piera Federico et al. Cancers
- Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- (2020) Weijia Zhao et al. ACS Omega
- Cardiac glycosides inhibit cancer through Na/K-ATPase-dependent cell death induction
- (2020) Xinran Geng et al. BIOCHEMICAL PHARMACOLOGY
- TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
- (2019) Hui-Huang Lai et al. Molecular Oncology
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Emerging agents and regimens for hepatocellular carcinoma
- (2019) Xiao-Dong Zhu et al. Journal of Hematology & Oncology
- The other functions of the sodium pump
- (2019) Amir Askari CELL CALCIUM
- Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells
- (2019) Bingren Hu et al. OncoTargets and Therapy
- Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
- (2018) Steve P H Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- (2018) Michael J Curtis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Na+/K+ ATPase activity promotes invasion of endocrine resistant breast cancer cells
- (2018) Maitham A. Khajah et al. PLoS One
- Crosstalk between Na+,K+-ATPase and a volume-regulated anion channel in membrane microdomains of human cancer cells
- (2018) Takuto Fujii et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
- (2018) Won Young Tak et al. INVESTIGATIONAL NEW DRUGS
- Epigenetic events involved in OCT1-dependent impaired response of hepatocellular carcinoma to sorafenib
- (2018) Ruba Al-Abdulla et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardenolides: Insights from chemical structure and pharmacological utility
- (2018) Hesham R. El-Seedi et al. PHARMACOLOGICAL RESEARCH
- Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
- (2017) Yehuda Patt et al. ONCOLOGIST
- Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
- (2017) Yuelong Liang et al. Cancer Medicine
- Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
- (2016) Joleen M. Hubbard et al. Targeted Oncology
- Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma
- (2015) Liping Zhuang et al. Oncotarget
- A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells
- (2014) Joan Fernando et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
- (2013) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II
- (2013) Z. Meng et al. MOLECULAR CANCER THERAPEUTICS
- CaMKII , a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine
- (2012) Y. Gu et al. BLOOD
- Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
- (2012) Angela Gauthier et al. HEPATOLOGY RESEARCH
- Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
- (2012) Marie-José Blivet-Van Eggelpoël et al. JOURNAL OF HEPATOLOGY
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation
- (2010) Wei Zhao et al. ANTI-CANCER DRUGS
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
- (2009) S. Hu et al. CLINICAL CANCER RESEARCH
- ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
- (2009) Sebastien Cagnol et al. FEBS Journal
- Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action
- (2009) Shan Wang et al. Molecular Cancer
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More